Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).
週四，2seventy Bio Inc. (NASDAQ:TSVT)與Novo Nordisk A/S (NYSE:NVO)完成了資產購買協議。
Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease.
根據協議條款，Novo Nordisk收購了血友病A治療項目和2seventy的體內基因編輯技術（除了用於治療腫瘤和自身或異基因細胞治療自身免疫疾病的基因編輯）的權利。
The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.
2seventy Bio團隊目前參與該項目，並將加入Novo Nordisk，並繼續推進技術發展。
Related: FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer.
相關:FDA批准Bristol-Myers/2seventy Bio的Abecma用於更早期的優先治療經過治療的血液癌症患者，並以更新的附加警告標籤指出其次癌症風險。
The program is based on the original research agreement, established in 2019, which focused on a gene editing therapy for Hemophilia A.
該項目基於2019年簽署的原始研究協議，針對血友病A的基因編輯治療。
2seventy bio will focus exclusively on the commercialization and continued development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb & Co (NYSE:BMY).
2seventy Bio將專注於商業化和持續開發基於BCMA的CAR T細胞治療藥物Abecma的，與Bristol Myers Squibb & Co (NYSE:BMY)合作。Abecma （idecabtagene vicleucel），
"We are pleased to announce the completion of this APA with Novo Nordisk as we believe it will provide the appropriate resources for both the team and the science behind this important program," said Chip Baird, CEO, 2seventy bio.
“我們很高興宣佈完成與Novo Nordisk的資產購買協議，因爲我們相信，這將爲該重要項目背後的團隊和科學提供適當的資源，” 2seventy Bio首席執行官Chip Baird說道。
Under the terms of the agreement, 2seventy will potentially receive payments of up to $40 million.
根據協議條款，2seventy可能會獲得高達4000萬美元的款項。
2seventy will transfer the Hemophilia A program to Novo Nordisk, and the existing collaboration agreement will be terminated.
2seventy將把血友病A治療項目轉讓給Novo Nordisk，現有的合作協議將被終止。
Additionally, the divestiture will include the transfer of 2seventy Bio's megaTAL technology and a license to the underlying intellectual property.
此外，剝離將包括轉讓2seventy Bio的megaTAL技術和其底層知識產權的許可。
Price Action: TSVT shares are up 4.58% at $3.77 at last check Thursday.
TSVT股票在上週四最後一次查詢時上漲4.58％，報3.77美元。